Education And Debate
Alteplase for stroke: money and optimistic claims buttress the “brain attack” campaignCommentary: Who pays the guideline writers?Commentary: Thrombolysis in stroke: it works!
BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7339.723 (Published 23 March 2002) Cite this as: BMJ 2002;324:723
Related articles
- Editor's Choice Published: 23 March 2002; BMJ 324 doi:10.1136/bmj.324.7339.0/h
- This Week In The BMJ Published: 23 March 2002; BMJ 324 doi:10.1136/bmj.324.7339.0/f
- News Extra [these Stories Appear Only On The Web] Published: 07 October 2004; BMJ 329 doi:10.1136/bmj.329.7470.820-f
- Feature Published: 14 June 2013; BMJ 346 doi:10.1136/bmj.f3830
- Editorial Published: 14 December 2002; BMJ 325 doi:10.1136/bmj.325.7377.1375
- Paper Published: 14 December 2002; BMJ 325 doi:10.1136/bmj.325.7377.1391
See more
- Stroke: Take test for genetic variant to ensure clopidogrel works for prevention, says NICEBMJ May 19, 2023, 381 p1146; DOI: https://doi.org/10.1136/bmj.p1146
- David Oliver: What the plan for social care omittedBMJ September 10, 2021, 374 n2227; DOI: https://doi.org/10.1136/bmj.n2227
- Stroke: “striking reductions” are seen in number of people with symptoms seeking helpBMJ April 06, 2020, 369 m1406; DOI: https://doi.org/10.1136/bmj.m1406
- NICE recommends implantable monitor to identify atrial fibrillation after strokeBMJ January 14, 2020, 368 m133; DOI: https://doi.org/10.1136/bmj.m133
- Thrombectomy can be considered up to 24 hours after onset of stroke, says NICEBMJ November 23, 2018, 363 k4995; DOI: https://doi.org/10.1136/bmj.k4995
Cited by...
- Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances
- With a Little Help From My Friends: Seeking Consistent and Persuasive Evidence
- American Academy of Neurology replies to Jeanne Lenzer
- Why we can't trust clinical guidelines
- Application of a medicolegal approach in clinical stalemates
- When Disclosures Are More Interesting Than the Evidence
- Thrombolysis (Tissue Plasminogen Activator) in Stroke: A Medicolegal Quagmire
- Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
- Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial
- Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data
- Independent panel finds alteplase beneficial for acute stroke patients
- Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement
- Getting it right: industry sponsorship and medical research
- Quality Improvement and Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Cleveland Update
- Controversy: The Essence of Medical Debate
- Management of stroke
- Does declaration of competing interests affect readers' perceptions? A randomised trial
- Making progress with competing interests: Still some way to go
- Controversial stroke trial is under review following BMJ report
- An assessment of guidelines for prevention of ischemic stroke
- La main invisible du marketing
- The invisible hand of the marketing department
- Alteplase for stroke